| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL9R |
| Uniprot No | B9ZVT0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-332aa |
| 氨基酸序列 | MHLGSNCCKNGQTLLQRTCHGVSCCGWWFQAARSILGKGPSAQSLAGWTL ESEALRRDMGTWLLACICICTCVCLGVSVTGEGQGPRSRTFTCLTNNILR IDCHWSAPELGQGSSPWLLFTRLLAAHISASCGAVSAPSCCHLRQCSCHL TISPSLSTTACLGGSRSAWWTRSTCPGDTSNISSGHCILTWSISPALEPM TTLLSYELAFKKQEEAWEQAQHRDHIVGVTWLILEAFELDPGFIHEARLR VQMATLEDDVVEEERYTGQWSEWSQPVCFQAPQRQGPLIPPWGWPGNTLV AVSIFLLLTGPTYLLFKLSPRLGWGPTGPVCC |
| 预测分子量 | 62 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL9R重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Cloning and Functional Characterization of the Human Interleukin-9 Receptor*
**作者**：Renauld, J.C. 等 (1992)
**摘要**：该研究首次报道了人源IL9R cDNA的克隆及重组蛋白在哺乳动物细胞中的表达。实验证实重组IL9R能特异性结合IL-9.并激活下游STAT信号通路，为后续功能研究奠定基础。
---
2. **文献名称**：*IL-9 Receptor Signaling Requires Its Extracellular Domain for Optimal Activity*
**作者**：Demoulin, J.B. 等 (1999)
**摘要**：通过构建重组IL9R截短体，作者发现其胞外结构域对IL-9的高亲和力结合及JAK/STAT信号激活至关重要，揭示了受体结构与功能的关系。
---
3. **文献名称**：*Structural Insights into IL-9 Recognition by Anti-Allergy Antibodies Using Recombinant IL9R*
**作者**：Xiao, X. 等 (2020)
**摘要**：利用重组IL9R蛋白解析其晶体结构，筛选出特异性抗体阻断IL-9/IL9R互作，为过敏性疾病的靶向治疗提供新策略。
---
以上文献涵盖IL9R重组蛋白的早期功能解析、结构信号机制及治疗应用研究。如需扩展领域(如疾病模型)，可补充相关研究。
Interleukin-9 receptor (IL9R) is a cell surface protein belonging to the type I cytokine receptor family, which plays a critical role in mediating immune and inflammatory responses. The IL9R protein forms a heterodimeric complex with the common gamma chain (γc), a shared subunit among receptors for cytokines like IL-2. IL-4. and IL-7. This receptor is primarily expressed on hematopoietic cells, including T cells, mast cells, and eosinophils, and it binds specifically to interleukin-9 (IL-9), a pleiotropic cytokine involved in allergic inflammation, autoimmune disorders, and cancer progression.
Recombinant IL9R proteins are engineered versions of the receptor, typically produced in mammalian or insect cell systems to ensure proper post-translational modifications and ligand-binding activity. These proteins often include the extracellular domain of IL9Rα (the ligand-specific subunit) fused with tags like Fc regions or histidine for purification and detection. Researchers use recombinant IL9R to study IL-9 signaling mechanisms, screen therapeutic inhibitors, or develop diagnostic tools for diseases linked to IL-9 dysregulation, such as asthma, atopic dermatitis, and certain lymphomas.
The IL-9/IL9R axis has garnered attention for its dual role in immunity and pathology. While IL-9 promotes mast cell differentiation and Th9 cell function in host defense, its overexpression correlates with tissue fibrosis and tumor microenvironment modulation. Recombinant IL9R proteins enable structural studies (e.g., crystallography) to map binding interfaces and design targeted biologics. Antagonists blocking IL-9/IL9R interactions are under investigation as potential therapies for autoimmune and allergic conditions. Conversely, agonist strategies are explored to harness IL-9's anti-tumor effects in specific cancer contexts. As a research tool, recombinant IL9R continues to advance our understanding of cytokine networks and precision immunotherapies.
×
